Last reviewed · How we verify
Avacincaptad
At a glance
| Generic name | Avacincaptad |
|---|---|
| Sponsor | Aviceda Therapeutics, Inc. |
| Target | Complement C5 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Approved indications
- Geographic atrophy secondary to age-related macular degeneration
Common side effects
- Conjunctival hemorrhage
- Blurred vision
- Increased IOP
- Choroidal neovascularization
- Punctate keratitis
- Eye pain
- Retinal hemorrhage
- Vitreous floaters
- Ocular hypertension
- Blepharitis
- Corneal abrasion
Serious adverse events
- Endophthalmitis
- Retinal detachment
- Vitreous hemorrhage
- Vitritis
- Optic ischemic neuropathy
- Photopsia
- Vitreal cells
Key clinical trials
- Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy (PHASE3)
- Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) (PHASE2)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE1)
- A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
- A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration (PHASE4)
- Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD (PHASE2)
- A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (PHASE2)
- A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |